DR REDDYS LABORATORIES
|
DR REDDYS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 50.25 | 67.81 | 334.41 | 270.55 | 131.16 |
| CEPS(Rs) | 74.45 | 89.08 | 84.51 | 69.12 | 40.24 |
| DPS(Rs) | 8.00 | 8.00 | 40.00 | 40.00 | 30.00 |
| Book NAV/Share(Rs) | 452.01 | 400.54 | 1,686.06 | 1,388.98 | 1,145.98 |
| Tax Rate(%) | 22.90 | 25.45 | 22.54 | 25.48 | 28.71 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.15 | 26.18 | 28.32 | 25.74 | 17.49 |
| EBIT Margin(%) | 17.11 | 24.39 | 26.32 | 25.10 | 14.65 |
| Pre Tax Margin(%) | 16.00 | 23.53 | 25.71 | 24.52 | 14.21 |
| PAT Margin (%) | 12.34 | 17.54 | 19.91 | 18.27 | 10.13 |
| Cash Profit Margin (%) | 18.45 | 22.76 | 25.16 | 23.34 | 15.54 |
| Performance Ratios | |||||
| ROA(%) | 8.03 | 13.41 | 16.08 | 15.01 | 8.08 |
| ROE(%) | 11.69 | 18.61 | 21.76 | 21.36 | 11.93 |
| ROCE(%) | 13.75 | 23.25 | 26.86 | 26.22 | 14.59 |
| Asset Turnover(x) | 0.65 | 0.76 | 0.81 | 0.82 | 0.80 |
| Sales/Fixed Asset(x) | 0.84 | 1.07 | 1.12 | 1.01 | 0.96 |
| Working Capital/Sales(x) | 2.54 | 2.72 | 1.84 | 2.08 | 2.69 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.20 | 0.94 | 0.89 | 0.99 | 1.04 |
| Receivable days | 103.79 | 95.44 | 99.54 | 103.01 | 98.60 |
| Inventory Days | 79.94 | 75.27 | 73.12 | 73.65 | 81.57 |
| Payable days | 84.78 | 96.23 | 108.56 | 108.07 | 99.98 |
| Valuation Parameters | |||||
| PER(x) | 24.97 | 16.87 | 3.68 | 3.42 | 32.83 |
| PCE(x) | 16.85 | 12.84 | 14.57 | 13.37 | 21.40 |
| Price/Book(x) | 2.78 | 2.86 | 3.65 | 3.33 | 3.76 |
| Yield(%) | 0.64 | 0.70 | 0.65 | 0.87 | 0.70 |
| EV/Net Sales(x) | 3.24 | 2.99 | 3.68 | 3.11 | 3.37 |
| EV/Core EBITDA(x) | 13.97 | 10.12 | 11.66 | 10.35 | 17.08 |
| EV/EBIT(x) | 18.93 | 12.26 | 13.96 | 12.37 | 23.00 |
| EV/CE(x) | 2.39 | 2.55 | 3.40 | 3.11 | 3.21 |
| M Cap / Sales | 3.11 | 2.92 | 3.67 | 3.12 | 3.33 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.24 | 16.54 | 13.54 | 14.50 | 13.11 |
| Core EBITDA Growth(%) | -19.00 | 9.26 | 19.22 | 74.14 | 2.18 |
| EBIT Growth(%) | -27.58 | 8.01 | 19.07 | 96.10 | 5.93 |
| PAT Growth(%) | -27.38 | 2.64 | 23.75 | 106.52 | 11.83 |
| EPS Growth(%) | -25.89 | -79.72 | 23.60 | 106.27 | 11.83 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.20 | 0.14 | 0.07 | 0.06 | 0.18 |
| Current Ratio(x) | 1.79 | 1.92 | 2.59 | 2.38 | 1.82 |
| Quick Ratio(x) | 1.34 | 1.37 | 1.92 | 1.82 | 1.30 |
| Interest Cover(x) | 15.43 | 28.15 | 43.09 | 43.36 | 32.96 |
| Total Debt/Mcap(x) | 0.07 | 0.05 | 0.02 | 0.02 | 0.05 |
Compare Financial Ratios of peers of DR REDDYS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DR REDDYS LABORATORIES | ₹114,733.7 Cr | -0.1% | 8.9% | 1.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,989.0 Cr | 1.7% | 6.4% | 12.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,471.0 Cr | 3% | 2.8% | 0.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹161,290.0 Cr | 2.3% | 9.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹117,820.0 Cr | 0.3% | 6.1% | -3.7% | Stock Analytics | |
| MANKIND PHARMA | ₹104,535.0 Cr | 1.8% | 6.7% | 8% | Stock Analytics | |
DR REDDYS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR REDDYS LABORATORIES | -0.1% |
8.9% |
1.9% |
| SENSEX | 0.9% |
4.2% |
-6% |
You may also like the below Video Courses
